Thanks to high rebates and payer hardball, Gilead is in a tough spot with its hepatitis C drugs, including its all-genotype treatment Epclusa and the once-high-flying Harvoni. In response, the company did something previously unheard of in pharma.
AbbVie inked a deal with the Medicines Patent Pool to boost access to hep C drug Mavyret in nearly 100 low- and middle-income countries and territories.
Merck lost out when a judge nixed $200 million in patent damages, citing misconduct and fabricated testimony. Now it wants the Supreme Court to intervene.
